Uncommon opportunistic yeast bloodstream infections from Qatar

Medical Mycology

Volumn 52, Issue 5, 2014, Pages 549-553

  Taj Aldeen, Saad J ^a   Abdulwahab, Atqah ^b,c   Kolecka, Anna ^d   Deshmukh, Anand ^a   Meis, Jacques F ^e,f   Boekhout, Teun ^d,g,h,i  

^a Department of Laboratory Medicine and Pathology ^*  (Qatar)

^b HAMAD MEDICAL CORPORATION   (Qatar)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^d CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h SECOND MILITARY MEDICAL UNIVERSITY   (China)

ⁱ INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

antifungal susceptibility; bloodstream infections; MALDI TOF MS; outcome; risk factors; uncommon yeasts

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; GENOMIC DNA; INTERNAL TRANSCRIBED SPACER 1; ISAVUCONAZOLE; POSACONAZOLE; RIBOSOME DNA; VORICONAZOLE; ANTIFUNGAL AGENT; AMPHOTERICIN B LIPID COMPLEX; ECHINOCANDIN;

ADOLESCENT; ADULT; ANAMORPH; ANTIFUNGAL RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; CANDIDA DUBLINIENSIS; CANDIDA INTERMEDIA; CANDIDA KRUSEI; CANDIDA PARARUGOSA; CHILD; CLAVISPORA LUSITANIAE; CLINICAL ARTICLE; FEMALE; FUNGEMIA; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; INFANT; KLUYVEROMYCES MARXIANUS; LINDNERA FABIANII; LODDEROMYCES ELONGISPORUS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEYEROZYMA GUILLIERMONDII; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; OPPORTUNISTIC INFECTION; QATAR; TELEOMORPH; TIME OF FLIGHT MASS SPECTROMETRY; WICKERHAMOMYCES ANOMALUS; YARROWIA LIPOLYTICA; AGED; CLASSIFICATION; GENETICS; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; MICROBIOLOGY; MORTALITY; NEWBORN; OPPORTUNISTIC INFECTIONS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY CARE CENTER; TREATMENT OUTCOME; VERY ELDERLY; YEAST; YOUNG ADULT; ANTIFUNGAL SUSCEPTIBILITY; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOMES RESEARCH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FUNGEMIA; HUMANS; INFANT; INFANT, NEWBORN; MALE; OPPORTUNISTIC INFECTIONS; QATAR; RETROSPECTIVE STUDIES; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TERTIARY CARE CENTERS; TREATMENT OUTCOME; YEASTS; YOUNG ADULT;

EID: 84903147951     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmycol/myu016     Document Type: Article

References (26)

1. Morgan J, Meltzer MI, Plikaytis BD et al., Excess mortality, hospital stay, and cost due to candidemia case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-547.
2. Colombo AL, Guimaraes T, Silva LR et al., Prospective observational study of candidemia in Sa?o Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 2007; 28: 570-576.
3. Burgos A, Zaoutis TE, Dvorak CC et al., Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008; 121: e1286-e1294.
4. Neu N, Malik M, Lunding A et al., Epidemiology of candidemia at a children's hospital, 2002 to 2006. Pediatr Infect Dis J 2009; 28: 806-809.
5. Zaoutis TE, Prasad PA, Localio AR et al., Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010; 51: e38-e45.
6. Wisplinghoff H, Bischoff T, Tallent SM et al., Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
7. Cantón E, Pemán J, Quindós G et al., Prospective multicenter study of the epidemiology, molecular identification, and antifun-gal susceptibility of Candida parapsilosis, Candida orthopsilo-sis, and Candida metapsilosis isolated from patients with can-didemia. Antimicrob Agents Chemother 2011; 55: 5590-5596.
8. Bassetti M, Righi E, Costa A et al., Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21.
9. Brown GD, Denning DW, Gow NAR et al., Hidden killers: human fungal infections. Sci Transl Med 2012; 4: 1-9.
10. Kurzmann CP, Fell JW, Boekhout T, (eds.) The Yeasts, A Tax-onomic Study, 5th edn. Elsevier, 2011.
11. De Pauw B, Walsh TJ, Donnelly JP et al., Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
12. Bolano A, Stinchi S, Preziosi R et al., Rapid methods to extract DNA and RNA from Cryptococcus neoformans. FEMS Yeast Res 2001; 1: 221-224.
13. Okoli I, Oyeka CA, Kwon-Chung KJ et al., Cryptotrichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar. FEMS Yeast Res 2007; 7: 339-350.
14. Cendejas-Bueno E, Kolecka A, Alastruey-Lzquierdo A et al., Reclassification of the Candida haemulonii complex; C. duobushaemulonii sp. nov. (C. haemulonii group II) and C. haemulonii var. vulnera var. nov.: two multiresistant human pathogenic yeasts. J Clin Microbiol 2012; 50: 3641-3651.
15. Kolecka A, Khayhan K, Groenewald M et al., MALDI-TOF MS identification of medically relevant species of arthroconidial yeasts. J Clin Microbiol 2013; 51: 2941-2500.
16. Taj-Aldeen SJ, Al-Ansari N, El Shafei S et al., Molecular identification and susceptibility of Trichosporon species isolated from clinical specimen in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J Clin Microbiol 2009; 47: 1791-1799.
17. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, approved standard, 4th supplement, document M27-S4. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
18. Diekema DJ, Messer SA, Boyken LB et al., In vitro activity of seven systematically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 2009; 47: 3170-3177.
19. Taj-Aldeen SJ, Kolecka A, Boesten R et al., Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern. Infection 2014. doi:10.1007/s15010-0570-4.
20. Pemán J, Cantón E, Quindós G et al., Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother 2012; 67: 1181-1187.
21. Groenewald M, Boekhout T, Neuvéglise C et al. Yarrowia lipolytica: safety assessment of an oleaginous yeast with great industrial potential. Crit Rev Microbiol 2013. doi:10.3109/1040841X.2013.770386.
22. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. Lod-deromyces elongisporus masquerading as Candida parapsilosis as cause of bloodstream infections. J Clin Microbiol 2008; 46: 374-376.
23. Ahmed S, Khan ZU, Johny M et al., Isolation of Lodderomyces elongisporus from the catheter tip of a fungemia patient in the Middle East. Case Rep Med 2013; 560406. doi:10.1155/2013/560406.
24. Gomez-Lopez A, Pan D, Cuesta I et al., Molecular identification and susceptibility profile in vitro of the emerging pathogen Candida kefyr. Diagn Microbiol Infect Dis 2010; 66: 116-119.
25. Schmitt-Hoffmann A, Roos B, Heep M et al., Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 279-285.
26. Schmitt-Hoffmann A, Roos B, Maares J et al., Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 286-293.